Evidence map›Paper›PMID 32868354›Full record

ArticleBMJ open2020

Point-of-care viral load testing among adolescents and youth living with HIV in Haiti: a protocol for a randomised trial to evaluate implementation and effect.

Lindsey K Reif, Marie Elmase Belizaire, Grace Seo, Vanessa Rouzier, Patrice Severe, Joseph Marie Joseph, Bernadette Joseph, Sandra Apollon, Elaine J Abrams, Stephen M Arpadi and 5 more

Registry-linked trialOpen access · goldAbstract readClinical Trial Protocol
In one paragraph

Article in BMJ open, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03288246 (Point-of-care Viral Load Testing Among HIV-infected Adolescents in Haiti), which is not on this map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.1field-weighted citation impact, top 48% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03288246 nacompletednot on this map

Point-of-care Viral Load Testing Among HIV-infected Adolescents in Haiti

TypeinterventionalSponsorWeill Medical College of Cornell UniversityRan2018 to 2020Enrolled150ConditionsHIVArmspoint-of-care viral load test
3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 3 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 4 institutions in 2 countries.

Lindsey K ReifCenter for Global Health, Department of Medicine, Weill Cornell Medicine, New York, New York, USA lir2020@med.cornell.edu.ORCID 0000-0003-3427-4475
Marie Elmase BelizaireGHESKIO, Port-au-Prince, Ouest, Haiti.
Grace SeoCenter for Global Health, Department of Medicine, Weill Cornell Medicine, New York, New York, USA.
Vanessa RouzierCenter for Global Health, Department of Medicine, Weill Cornell Medicine, New York, New York, USA.
Patrice SevereGHESKIO, Port-au-Prince, Ouest, Haiti.
Joseph Marie JosephGHESKIO, Port-au-Prince, Ouest, Haiti.
Bernadette JosephGHESKIO, Port-au-Prince, Ouest, Haiti.
Sandra ApollonGHESKIO, Port-au-Prince, Ouest, Haiti.
Elaine J AbramsDepartment of Epidemiology, Mailman School of Public Health, Columbia University Irving Medical Center, New York, New York, USA.
Stephen M ArpadiICAP at Columbia University, Mailman School of Public Health, Columbia University Irving Medical Center, New York, New York, USA.
Batya ElulDepartment of Epidemiology, Mailman School of Public Health, Columbia University Irving Medical Center, New York, New York, USA.
Jean W PapeCenter for Global Health, Department of Medicine, Weill Cornell Medicine, New York, New York, USA.
Margaret L McNairyDivision of General Internal Medicine, Department of Medicine, Weill Cornell Medicine, New York, New York, USA.
Daniel W FitzgeraldCenter for Global Health, Department of Medicine, Weill Cornell Medicine, New York, New York, USA.
Louise KuhnICAP at Columbia University, Mailman School of Public Health, Columbia University Irving Medical Center, New York, New York, USA.
Cornell University · USGheskio Centers · HTColumbia University · USColumbia University Irving Medical Center · US

Funding

GHESKIO HIV Clinical Trial UnitUM1AI069421 · NIAID · GHESKIO CENTER · PI JEAN WILLIAM PAPE · 2012 to 2026
$23.6M
GHESKIO HIV Clinical Trial UnitU01AI069421 · NIAID · GHESKIO CENTER · PI PAPE, JEAN WILLIAM · 2007 to 2011
$8.4M
Training in pharmacokinetic and pharmacodynamics research in HIV and tuberculosisD43TW010062 · FIC · WEILL MEDICAL COLL OF CORNELL UNIV · PI FITZGERALD, DANIEL W · 2015 to 2019
$1.8M
Global Health Research Training in HIV and TuberculosisK24AI098627 · NIAID · WEILL MEDICAL COLL OF CORNELL UNIV · PI FITZGERALD, DANIEL W · 2012 to 2022
$1.8M
Research Training Program in Adolescent HIV in HaitiD43TW011295 · FIC · GHESKIO CENTER · PI PAPE, JEAN WILLIAM · 2020 to 2024
$1.6M
FIC NIH HHS D43 TW010062FIC NIH HHS D43 TW011295NIAID NIH HHS K24 AI098627NIAID NIH HHS U01 AI069421NIAID NIH HHS UM1 AI069421
6 · The paper itself

Abstract

introductionAdolescents living with HIV have poor antiretroviral therapy (ART) adherence and viral suppression outcomes. Viral load (VL) monitoring could reinforce adherence but standard VL testing requires strong laboratory capacity often only available in large central laboratories. Thus, coordinated transport of samples and results between the clinic and laboratory is required, presenting opportunities for delayed or misplaced results. Newly available point-of-care (POC) VL testing systems return test results the same day and could simplify VL monitoring so that adolescents receive test results faster which could strengthen adherence counselling and improve ART adherence and viral suppression. METHODS AND ANALYSIS: This non-blinded randomised clinical trial is designed to evaluate the implementation and effectiveness of POC VL testing compared with standard laboratory-based VL testing among adolescents and youth living with HIV in Haiti. A total of 150 participants ages 10-24 who have been on ART for >6 months are randomised 1:1 to intervention or standard arms. Intervention arm participants receive a POC VL test (Cepheid Xpert HIV-1 Viral Load system) with same-day result and immediate ART adherence counselling. Standard care participants receive a laboratory-based VL test (Abbott m2000sp/m2000rt) with the result available 1 month later, at which time they receive ART adherence counselling. VL testing is repeated 6 months later for both arms. The primary objective is to describe the implementation of POC VL testing compared with standard laboratory-based VL testing. The secondary objective is to evaluate the effect of POC VL testing on VL suppression at 6 months and participant comprehension of the correlation between VL and ART adherence. ETHICS AND DISSEMINATION: This study is approved by GHESKIO, Weill Cornell Medicine and Columbia University ethics committees. This trial will provide critical data to understand if and how POC VL testing may impact adolescent ART adherence and viral suppression. If effective, POC VL testing could routinely supplement standard laboratory-based VL testing among high-risk populations living with HIV. TRIAL REGISTRATION NUMBER: NCT03288246.

Indexed as

HIV InfectionsPoint-of-Care SystemsAdolescentAdultAnti-Retroviral AgentsChildHaitiHumansRandomized Controlled Trials as TopicViral LoadYoung AdultAnti-Retroviral Agentsclinical trialsHIV & AIDSpaediatrics

Identifiers

PMID32868354
PMCPMC7462242
OpenAlexW3082732446

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.